Canada’s Drug Agency (CDA-AMC) recommends that Ryaltris should not be reimbursed by public drug plans for the symptomatic treatment of moderate-to-severe seasonal allergic rhinitis and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.
